Crucell N.V. Discovers Human Monoclonal Antibodies for the Prevention and Treatment of the Avian Flu Virus; The Antibody Provides Immediate Protection and Neutralizes the Broadest Range of H5N1 Strains

LEIDEN, NETHERLANDS--(Marketwire - September 27, 2007) - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced the discovery of a set of human monoclonal antibodies against H5N1. These results, demonstrating the potential of human monoclonal antibodies for pandemic preparedness, were presented today at the 5th International Bird Flu Summit held in Las Vegas, Nevada.